Pancreatic cancer trial reports doubled median survival

A late-stage study of Revolution Medicines' daraxonrasib reported median survival of 13.2 months versus 6.7 months for chemotherapy, according to a company press release. More complete results are expected at an upcoming cancer conference.

A late-stage clinical trial reported that the experimental drug daraxonrasib extended survival for people with advanced pancreatic cancer. The public summary of the result comes from a company press release. The study enrolled patients whose disease had progressed after chemotherapy. Pancreatic cancer is often diagnosed late and has been difficult to treat. Key findings: - The trial reported median overall survival of 13.2 months for patients who received daraxonrasib, compared with 6.7 months for those who received chemotherapy alone. - The information released so far is from a company press release; fuller data will be presented at an upcoming cancer conference. - The trial population consisted of patients with disease that progressed after prior chemotherapy. - Reported side effects include rashes and gastrointestinal issues, and one public account noted visible facial bleeding in a trial participant. Summary: The reported survival difference represents a notable result in a cancer type that has been hard to treat. Full trial data will be shared at a professional cancer meeting, and the company has said it is pursuing regulatory review that could be expedited under a new FDA voucher program; next procedural and clinical details are undetermined at this time.